Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients.

Frontiers in immunology

Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S.
PMID: 28611778
Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017.

IFN-lambda (IFNλ) is a member of the type III IFN family and is reported to possess anti-pathogen, anti-cancer, and immunomodulatory properties; however, there are limited data regarding its impact on host immune responses CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01204762.

Cite
Phillips S, Mistry S, Riva A, et al. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017;8:621doi: 10.3389/fimmu.2017.00621.
Phillips, S., Mistry, S., Riva, A., Cooksley, H., Hadzhiolova-Lebeau, T., Plavova, S., Katzarov, K., Simonova, M., Zeuzem, S., Woffendin, C., Chen, P. J., Peng, C. Y., Chang, T. T., Lueth, S., De Knegt, R., Choi, M. S., Wedemeyer, H., Dao, M., Kim, C. W., Chu, H. C., Wind-Rotolo, M., Williams, R., Cooney, E., & Chokshi, S. (2017). Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Frontiers in immunology, 8621. https://doi.org/10.3389/fimmu.2017.00621
Phillips, Sandra, et al. "Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients." Frontiers in immunology vol. 8 (2017): 621. doi: https://doi.org/10.3389/fimmu.2017.00621
Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, Katzarov K, Simonova M, Zeuzem S, Woffendin C, Chen PJ, Peng CY, Chang TT, Lueth S, De Knegt R, Choi MS, Wedemeyer H, Dao M, Kim CW, Chu HC, Wind-Rotolo M, Williams R, Cooney E, Chokshi S. Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol. 2017 May 29;8:621. doi: 10.3389/fimmu.2017.00621. eCollection 2017. PMID: 28611778; PMCID: PMC5446997.
Copy Download .nbib Format: NLM
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.

Cancer immunology research

Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA.
PMID: 34389558
Cancer Immunol Res. 2021 Oct;9(10):1202-1213. doi: 10.1158/2326-6066.CIR-20-0983. Epub 2021 Aug 13.

Outcomes for patients with melanoma have improved over the past decade as a result of the development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand 1 (PD-L1). However, these...

Cite
Hodi FS, Wolchok JD, Schadendorf D, et al. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunol Res. 2021;9(10):1202-1213doi: 10.1158/2326-6066.CIR-20-0983.
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., Tang, H., Wind-Rotolo, M., Rizzo, J. I., Jackson, D. G., & Ascierto, P. A. (2021). TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer immunology research, 9(10), 1202-1213. https://doi.org/10.1158/2326-6066.CIR-20-0983
Hodi, F Stephen, et al. "TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma." Cancer immunology research vol. 9,10 (2021): 1202-1213. doi: https://doi.org/10.1158/2326-6066.CIR-20-0983
Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer Immunol Res. 2021 Oct;9(10):1202-1213. doi: 10.1158/2326-6066.CIR-20-0983. Epub 2021 Aug 13. PMID: 34389558.
Copy Download .nbib Format: NLM
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Cancer cell

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A.
PMID: 33306984
Cancer Cell. 2021 Jan 11;39(1):122. doi: 10.1016/j.ccell.2020.11.015. Epub 2020 Dec 10.

No abstract available.

Cite
Grasso CS, Tsoi J, Onyshchenko M, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;39(1):122doi: 10.1016/j.ccell.2020.11.015.
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., Tran, P., Kim, Y. J., Puig-Saus, C., Campbell, K., Vega-Crespo, A., Quist, M., Martignier, C., Luke, J. J., Wolchok, J. D., Johnson, D. B., Chmielowski, B., Hodi, F. S., Bhatia, S., Sharfman, W., Urba, W. J., Slingluff, C. L., Diab, A., Haanen, J. B. A. G., Algarra, S. M., Pardoll, D. M., Anagnostou, V., Topalian, S. L., Velculescu, V. E., Speiser, D. E., Kalbasi, A., & Ribas, A. (2021). Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer cell, 39(1), 122. https://doi.org/10.1016/j.ccell.2020.11.015
Grasso, Catherine S, et al. "Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma." Cancer cell vol. 39,1 (2021): 122. doi: https://doi.org/10.1016/j.ccell.2020.11.015
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2021 Jan 11;39(1):122. doi: 10.1016/j.ccell.2020.11.015. Epub 2020 Dec 10. PMID: 33306984; PMCID: PMC7885306.
Copy Download .nbib Format: NLM
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

The Lancet. Oncology

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.
PMID: 34895481
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09.

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The...

Cite
Naranbhai V, Viard M, Dean M, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021;23(1):172-184doi: 10.1016/S1470-2045(21)00582-9.
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet. Oncology, 23(1), 172-184. https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai, Vivek, et al. "HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study." The Lancet. Oncology vol. 23,1 (2022): 172-184. doi: https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09. PMID: 34895481; PMCID: PMC8742225.
Copy Download .nbib Format: NLM
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

The Lancet. Oncology

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.
PMID: 34895481
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09.

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The...

Cite
Naranbhai V, Viard M, Dean M, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021;23(1):172-184doi: 10.1016/S1470-2045(21)00582-9.
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet. Oncology, 23(1), 172-184. https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai, Vivek, et al. "HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study." The Lancet. Oncology vol. 23,1 (2022): 172-184. doi: https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09. PMID: 34895481; PMCID: PMC8742225.
Copy Download .nbib Format: NLM
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.

Journal for immunotherapy of cancer

Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M.
PMID: 33658305
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001506.

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting the programmed death-1 receptor that improves survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). In contrast to other tumor types that respond to immunotherapy, factors such...

Cite
Ross-Macdonald P, Walsh AM, Chasalow SD, et al. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021;9(3)doi: 10.1136/jitc-2020-001506.
Ross-Macdonald, P., Walsh, A. M., Chasalow, S. D., Ammar, R., Papillon-Cavanagh, S., Szabo, P. M., Choueiri, T. K., Sznol, M., & Wind-Rotolo, M. (2021). Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. Journal for immunotherapy of cancer, 9(3), . https://doi.org/10.1136/jitc-2020-001506
Ross-Macdonald, Petra, et al. "Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC." Journal for immunotherapy of cancer vol. 9,3 (2021). doi: https://doi.org/10.1136/jitc-2020-001506
Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001506. PMID: 33658305; PMCID: PMC7931766.
Copy Download .nbib Format: NLM
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

The Lancet. Oncology

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.
PMID: 34895481
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09.

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The...

Cite
Naranbhai V, Viard M, Dean M, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021;23(1):172-184doi: 10.1016/S1470-2045(21)00582-9.
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet. Oncology, 23(1), 172-184. https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai, Vivek, et al. "HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study." The Lancet. Oncology vol. 23,1 (2022): 172-184. doi: https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09. PMID: 34895481.
Copy Download .nbib Format: NLM
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.

Clinical cancer research : an official journal of the American Association for Cancer Research

Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD.
PMID: 33837006
Clin Cancer Res. 2021 Aug 01;27(15):4287-4300. doi: 10.1158/1078-0432.CCR-20-4574. Epub 2021 Apr 09.

PURPOSE: To define dominant molecular and cellular features associated with PD-1/PD-L1 blockade resistance in metastatic urothelial cancer.EXPERIMENTAL DESIGN: We pursued an unbiased approach using bulk RNA sequencing data from two clinical trials to discover (IMvigor 210) and validate (CheckMate...

Cite
Wang L, Sfakianos JP, Beaumont KG, et al. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021;27(15):4287-4300doi: 10.1158/1078-0432.CCR-20-4574.
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., Wiklund, P., Oh, W. K., Szabo, P. M., Wind-Rotolo, M., Unsal-Kacmaz, K., Yao, X., Schadt, E., Sharma, P., Bhardwaj, N., Zhu, J., & Galsky, M. D. (2021). Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4287-4300. https://doi.org/10.1158/1078-0432.CCR-20-4574
Wang, Li, et al. "Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4287-4300. doi: https://doi.org/10.1158/1078-0432.CCR-20-4574
Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021 Aug 01;27(15):4287-4300. doi: 10.1158/1078-0432.CCR-20-4574. Epub 2021 Apr 09. PMID: 33837006; PMCID: PMC8338756.
Copy Download .nbib Format: NLM
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.

Clinical cancer research : an official journal of the American Association for Cancer Research

Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD.
PMID: 33837006
Clin Cancer Res. 2021 Aug 01;27(15):4287-4300. doi: 10.1158/1078-0432.CCR-20-4574. Epub 2021 Apr 09.

PURPOSE: To define dominant molecular and cellular features associated with PD-1/PD-L1 blockade resistance in metastatic urothelial cancer.EXPERIMENTAL DESIGN: We pursued an unbiased approach using bulk RNA sequencing data from two clinical trials to discover (IMvigor 210) and validate (CheckMate...

Cite
Wang L, Sfakianos JP, Beaumont KG, et al. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021;27(15):4287-4300doi: 10.1158/1078-0432.CCR-20-4574.
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., Wiklund, P., Oh, W. K., Szabo, P. M., Wind-Rotolo, M., Unsal-Kacmaz, K., Yao, X., Schadt, E., Sharma, P., Bhardwaj, N., Zhu, J., & Galsky, M. D. (2021). Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(15), 4287-4300. https://doi.org/10.1158/1078-0432.CCR-20-4574
Wang, Li, et al. "Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,15 (2021): 4287-4300. doi: https://doi.org/10.1158/1078-0432.CCR-20-4574
Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021 Aug 01;27(15):4287-4300. doi: 10.1158/1078-0432.CCR-20-4574. Epub 2021 Apr 09. PMID: 33837006; PMCID: PMC8338756.
Copy Download .nbib Format: NLM
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research

Ficial M, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-Rotolo M, Sticco-Ivins MA, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, Choueiri TK, Signoretti S.
PMID: 33219016
Clin Cancer Res. 2021 Mar 01;27(5):1371-1380. doi: 10.1158/1078-0432.CCR-20-3084. Epub 2020 Nov 20.

PURPOSE: We sought to validate levels of CD8EXPERIMENTAL DESIGN: Tumor tissues (nivo: RESULTS: In the nivo (but not evero) arm, patients with high-IF biomarker density (24/116, 20.7%) had higher ORR (45.8% vs. 19.6%, CONCLUSIONS: High levels of CD8

Cite
Ficial M, Jegede OA, Sant'Angelo M, et al. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2020;27(5):1371-1380doi: 10.1158/1078-0432.CCR-20-3084.
Ficial, M., Jegede, O. A., Sant'Angelo, M., Hou, Y., Flaifel, A., Pignon, J. C., Braun, D. A., Wind-Rotolo, M., Sticco-Ivins, M. A., Catalano, P. J., Freeman, G. J., Sharpe, A. H., Hodi, F. S., Motzer, R. J., Wu, C. J., Atkins, M. B., McDermott, D. F., Shukla, S. A., Choueiri, T. K., & Signoretti, S. (2021). Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1371-1380. https://doi.org/10.1158/1078-0432.CCR-20-3084
Ficial, Miriam, et al. "Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,5 (2021): 1371-1380. doi: https://doi.org/10.1158/1078-0432.CCR-20-3084
Ficial M, Jegede OA, Sant'Angelo M, Hou Y, Flaifel A, Pignon JC, Braun DA, Wind-Rotolo M, Sticco-Ivins MA, Catalano PJ, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Wu CJ, Atkins MB, McDermott DF, Shukla SA, Choueiri TK, Signoretti S. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 Mar 01;27(5):1371-1380. doi: 10.1158/1078-0432.CCR-20-3084. Epub 2020 Nov 20. PMID: 33219016; PMCID: PMC8443005.
Copy Download .nbib Format: NLM
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

SpringerPlus

Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD.
PMID: 27588258
Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016.

BACKGROUND AND PURPOSE: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor)...

Cite
Foster GR, Chayama K, Chuang WL, et al. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016;5(1):1365doi: 10.1186/s40064-016-2920-z.
Foster, G. R., Chayama, K., Chuang, W. L., Fainboim, H., Farkkila, M., Gadano, A., Gaeta, G. B., Hézode, C., Inada, Y., Heo, J., Kumada, H., Lu, S. N., Marcellin, P., Moreno, C., Roberts, S. K., Strasser, S. I., Thompson, A. J., Toyota, J., Paik, S. W., Vierling, J. M., Zignego, A. L., Cohen, D., McPhee, F., Wind-Rotolo, M., Srinivasan, S., Hruska, M., Myler, H., & Portsmouth, S. D. (2016). A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. SpringerPlus, 5(1), 1365. https://doi.org/10.1186/s40064-016-2920-z
Foster, Graham R, et al. "A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3." SpringerPlus vol. 5,1 (2016): 1365. doi: https://doi.org/10.1186/s40064-016-2920-z
Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016. PMID: 27588258; PMCID: PMC4990525.
Copy Download .nbib Format: NLM
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.

The Lancet. Oncology

Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M.
PMID: 34895481
Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09.

BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The...

Cite
Naranbhai V, Viard M, Dean M, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021;23(1):172-184doi: 10.1016/S1470-2045(21)00582-9.
Naranbhai, V., Viard, M., Dean, M., Groha, S., Braun, D. A., Labaki, C., Shukla, S. A., Yuki, Y., Shah, P., Chin, K., Wind-Rotolo, M., Mu, X. J., Robbins, P. B., Gusev, A., Choueiri, T. K., Gulley, J. L., & Carrington, M. (2022). HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet. Oncology, 23(1), 172-184. https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai, Vivek, et al. "HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study." The Lancet. Oncology vol. 23,1 (2022): 172-184. doi: https://doi.org/10.1016/S1470-2045(21)00582-9
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2022 Jan;23(1):172-184. doi: 10.1016/S1470-2045(21)00582-9. Epub 2021 Dec 09. PMID: 34895481; PMCID: PMC8742225.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries